/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Multimillion-dollar investment in EY Blockchain Analyzer delivers new upgrades for blockchain and cryptocurrency audit and tax services
EY today announced the launch of the second generation of EY Blockchain Analyzer, a blockchain analytics tool, at the annual EY Global Blockchain Summit. The summit convenes more than 200 executives, analysts and EY clients to offer a first-time demo of the full EY blockchain solutions suite and provide a comprehensive view of the state of the technology’s integration across industries.
Over the past two years, EY Blockchain Analyzer has undergone significant developments as part of a multimillion-dollar investment and is expected to be available for use by EY client-serving teams in 2019 across a selection of more than 100 EY Assurance clients that hold or trade cryptocurrencies or operate in the blockchain ecosystem. These developments include the support of multiple new cryptocurrencies on the platform, added functionality relevant to private and public blockchains, and a globally accessible and available platform.
The first generation of the EY Blockchain Analyzer was designed to facilitate EY audit teams in gathering an organization’s entire transaction data from multiple blockchain ledgers, to reconcile that data to EY clients’ books and records and to perform enhanced analytics, including trend analysis and identification of outliers.
Through this major upgrade, a version of this second generation EY Blockchain Analyzer is available for EY teams and non-audit clients as a business application that is accessible anytime and helps enable financial reporting, forensic investigations, transaction monitoring and tax calculations, to support EY teams and clients globally across Advisory, Tax and Transaction Advisory Services.
Paul Brody, EY Global Innovation Leader, Blockchain, says:
“With the second generation of EY Blockchain Analyzer, we are building a true platform solution that can be used for multiple purposes such as audit, tax and transaction monitoring, depending on client needs. From the start, we have had technologists and audit practitioners working together on this platform so we can keep our technology and audit methodology aligned and meet our professional standards.”
The latest version of EY Blockchain Analyzer being showcased at the EY Global Blockchain Summit supports analysis of zero-knowledge proof (ZKP) private transactions on the public Ethereum blockchain, as well as the Bitcoin, Bitcoin Cash, Ethereum, Ethereum Classic and Litecoin public blockchains. EY Blockchain Analyzer also supports private Ethereum, Quorum and Hyperledger blockchains.
Felice Persico, EY Global Vice Chair – Assurance, says:
“As technologies continue to evolve, so too does the need to integrate transformative capabilities into our audit tools. The second generation of EY Blockchain Analyzer will provide valuable evidence for audits in various sectors.”
In addition to transaction analysis, the new version of EY Blockchain Analyzer will support tax calculation for crypto-assets. Leveraging the insights and assets acquired with the Andy Crypto-Asset Accounting and Tax (AndyCAAT) tool in 2018 for better visibility into cryptocurrency transactions and inventory, the newest version of this technology can automatically calculate capital gains and losses on transactions in compliance with US tax law.
Kate Barton, EY Global Vice Chair – Tax, says:
“Integrating the prior acquisition of AndyCAAT into the global EY network for tax services exemplifies our commitment to digital innovation in the tax area. We are committed to providing clients with seamless one-stop solutions from transaction monitoring and security to tax calculation. With EY Blockchain Analyzer, we are delivering on that vision.”
EY will gradually expand the geographic coverage for tax calculation globally after the 2019 tax year. EY engagement teams have served more than 100 clients using AndyCAAT to help calculate their taxes this year and, from next year, the tax functionality within EY Blockchain Analyzer will be available to all EY Tax practitioners.
In addition to the second generation of EY Blockchain Analyzer, EY has announced a suite of blockchain solutions and upgrades at the EY Global Blockchain Summit, including the release of the first generation of EY Ops Chain Public Edition into the public domain, as well as the launch of EY Smart Contract Analyzer and the second generation of EY Ops Chain.
SOURCE EY
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
SCHWAZZE
Schwazze Announces Fourth Quarter and Full Year 2023 Financial Results
FY 2023 Revenue of $172.4 Million; Income from Operations of $3.3 Million; Adjusted EBITDA of $53.4 Million or 31% of Revenue
Generated $12.2 Million of Operating Cash Flow in FY 2023
DENVER, March 27, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the fourth quarter and full year ended December 31, 2023.
“This past year, the Schwazze team delivered solid top-line growth in two highly competitive markets with 31% adjusted EBITDA margins and improved operating cash flow,” said Forrest Hoffmaster, Interim CEO of Schwazze. “We continued to sharpen our retail strategy while expanding our store footprint by more than 50% to 63 dispensaries across our two markets. Although the Colorado and New Mexico markets were pressured in 2023, we have built a solid foundation with best-in-class service for our patients and customers. Internally, we are also relentlessly focused on maximizing the operating efficiencies of our manufacturing and cultivation facilities to drive higher yields, improved flower quality, and greater output.”
“With strong demand and over 680 recreational retail stores at year-end, the competitive landscape in Colorado is fierce, underscoring the importance of our investments in and attention to elevating the customer experience. We significantly outpaced the market in Q4 on a sequential and year-over-year basis and expect to bolster our growth through improvements in customer acquisition, retention, and loyalty, as well as in the overall retail experience. Additionally, we are beginning to see wholesale pricing stabilize, which we anticipate will continue based on plant counts and ongoing retail pricing pressure.”
“In New Mexico, the proliferation of new licenses has led to increased competition and aggressive pricing strategies from certain players. Cannabis sales in the state were up 18% across a store base that was over 50% higher year-over-year in Q4, leading to lower average revenue per store. While we are beginning to see a slow-down in net new store openings, we anticipate a challenging market ahead. We remain focused on cost optimization and asset utilization while implementing a balanced pricing and promotional strategy to drive traffic into our stores, where we believe we excel in delivering an elevated retail experience. We are committed to fulfilling our promise of being the retailer of choice in New Mexico.”
“Looking ahead, we are optimistic about the regulatory momentum in the industry at large. In the meantime, we will continue to elevate the customer experience, improve our loyalty program, increase our cost efficiencies, and enhance our retail assets. Our team has a demonstrated track record of executing in competitive markets like Colorado and New Mexico where we remain one of the largest operators. We look forward to driving growth and profitability across each of our markets in 2024.”
Fourth Quarter 2023 Financial Summary
$ in Thousands USD |
Q4 2023 |
Q3 2023 |
Q4 2022 |
Total Revenue |
$43,325 |
$46,747 |
$40,147 |
Gross Profit |
$7,034 |
$21,438 |
$21,719 |
Adjusted Gross Profit[1] |
$20,180 |
$21,438 |
$21,719 |
Operating Expenses |
$23,276 |
$12,514 |
$24,224 |
Income (Loss) from Operations |
$(16,242) |
$8,924 |
$(2,505) |
Adjusted EBITDA[2] |
$10,953 |
$14,119 |
$13,285 |
Operating Cash Flow |
$3,452 |
$6,946 |
$6,260 |
Full Year 2023 Financial Summary
$ in Thousands USD |
FY 2023 |
FY 2022 |
Total Revenue |
$172,448 |
$159,379 |
Gross Profit |
$76,024 |
$80,289 |
Adjusted Gross Profit1 |
$89,170 |
$86,830 |
Operating Expenses |
$72,735 |
$67,434 |
Income from Operations |
$3,289 |
$12,855 |
Adjusted EBITDA2 |
$53,412 |
$52,010 |
Operating Cash Flow |
$12,201 |
$6,694 |
___________________________ |
1 Adjusted Gross Profit is a non-GAAP measure as defined by the SEC and represents gross profit excluding non-cash inventory adjustments. The Company uses Adjusted Gross Profit as it believes it better explains the results of its core business. See “ADJUSTED GROSS PROFIT RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release. |
2 Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release. |
Full Year 2023 Operational Highlights
- Expanded the Company’s retail footprint by more than 50% in New Mexico and Colorado to 63 dispensaries.
- Completed the acquisition of Everest Apothecary, adding 14 dispensaries, one cultivation facility, and one manufacturing plant to the Company’s New Mexico operations.
- Acquired Standing Akimbo, the largest medical cannabis dispensary in Colorado, and opened the Company’s first medical dispensary in Colorado Springs under the Standing Akimbo banner.
- Acquired two Colorado retail dispensaries in Fort Collins and Garden City from Smokey’s.
- Unveiled an enhanced, custom ecommerce platform in New Mexico under the R. Greenleaf banner.
- Increased wholesale penetration in Colorado and New Mexico by over 3x year-over-year to more than 27% total door penetration in both states.
- Grew Lowell Farms pre-roll sales by over 250% in Colorado where it is now the #1 pre-roll in the state. In addition, Lowell is in six of the largest Colorado accounts and will be available for wholesale in New Mexico starting April 1st, 2024.
- Grew sales with Wana, our fan-favorite gummies brand, by 48% in New Mexico where it is now in 130 doors with eight of the top ten accounts in the state.
Fourth Quarter 2023 Financial Results
Total revenue in the fourth quarter of 2023 increased 8% to $43.3 million compared to $40.1 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period and increased wholesale revenue, partially offset by pricing pressure from the proliferation of new licenses in New Mexico.
Gross profit for the fourth quarter of 2023 was $7.0 million or 16.2% of total revenue, compared to $21.7 million or 54.1% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. Adjusted gross profit, which excludes non-cash inventory adjustments, for the fourth quarter of 2023 was $20.2 million or 46.6% of revenue.
Operating expenses for the fourth quarter of 2023 were $23.3 million compared to $24.2 million for the same quarter last year. The decrease was primarily due to a lower impairment charge in the fourth quarter of 2023. This was partially offset by an increase in four-wall SG&A expenses associated with the 22 additional stores in Colorado and New Mexico that are still ramping, as well as greater salaries and stock-based compensation.
Loss from operations for the fourth quarter of 2023 was $16.2 million compared to $2.5 million in the same quarter last year. The decrease was driven by the aforementioned lower gross profit, primarily related to the non-cash inventory adjustment. Net loss was $33.9 million for the fourth quarter of 2023 compared to $27.3 million for the same quarter last year.
Adjusted EBITDA for the fourth quarter of 2023 was $11.0 million or 25.3% of revenue, compared to $13.3 million or 33.1% of revenue for the same quarter last year. The decrease in Adjusted EBITDA margin was primarily driven by higher operating expenses associated with the 22 additional stores that are still ramping.
As of December 31, 2023, cash and cash equivalents were $19.2 million compared to $38.9 million on December 31, 2022. Total debt as of December 31, 2023, was $156.8 million compared to $127.8 million on December 31, 2022.
Conference Call
The Company will conduct a conference call today, March 27, 2024, at 5:00 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2023.
Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].
Date: Wednesday, March 27, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 38840334
Webcast: SHWZ Q4 & FY 2023 Earnings Call
The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.
Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 840334
If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.
Schwazze (OTCQX: SHWZ) (Cboe: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.
Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.
Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.
Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars
For the Three Months Ended |
For the Twelve Months Ended |
||||||||||
December 31, |
December 31, |
||||||||||
2023 |
2022 |
2023 |
2022 |
||||||||
(Unaudited) |
(Unaudited) |
(Audited) |
(Audited) |
||||||||
Operating Revenues |
|||||||||||
Retail |
$ |
39,592,779 |
$ |
36,868,429 |
$ |
155,463,816 |
$ |
141,254,893 |
|||
Wholesale |
3,730,749 |
3,158,670 |
16,765,425 |
17,819,938 |
|||||||
Other |
1,287 |
120,188 |
218,545 |
304,388 |
|||||||
Total Revenue |
43,324,815 |
40,147,287 |
172,447,786 |
159,379,219 |
|||||||
Total Cost of Goods & Services |
36,291,059 |
18,428,528 |
96,424,150 |
79,090,461 |
|||||||
Gross Profit |
7,033,756 |
21,718,759 |
76,023,636 |
80,288,758 |
|||||||
Operating Expenses |
|||||||||||
Selling, General and Administrative Expenses |
10,848,029 |
8,922,627 |
39,916,518 |
29,036,962 |
|||||||
Professional Services |
1,115,457 |
1,112,975 |
3,558,501 |
6,722,554 |
|||||||
Loss on Impairment |
1,810,890 |
8,011,405 |
1,801,740 |
8,011,405 |
|||||||
Salaries |
6,561,800 |
5,292,996 |
23,883,354 |
20,990,290 |
|||||||
Stock Based Compensation |
2,952,669 |
883,890 |
3,574,831 |
2,672,713 |
|||||||
Total Operating Expenses |
23,288,845 |
24,223,893 |
72,734,944 |
67,433,924 |
|||||||
Income from Operations |
(16,255,089) |
(2,505,134) |
3,288,692 |
12,854,834 |
|||||||
Other Income (Expense) |
|||||||||||
Interest Expense, net |
(8,112,391) |
(6,827,557) |
(32,069,082) |
(30,139,645) |
|||||||
Unrealized Gain (Loss) on Derivative Liabilities |
1,384,228 |
(9,690,200) |
15,870,233 |
18,414,760 |
|||||||
Other Loss |
68,400 |
3,736 |
68,400 |
24,136 |
|||||||
Loss on Business Disposition |
(1,968,807) |
(4,684,366) |
(1,968,807) |
(4,684,366) |
|||||||
Unrealized Gain (Loss) on Investments |
– |
3,083 |
1,816 |
(39,270) |
|||||||
Total Other Income (Expense) |
(8,628,570) |
(21,195,304) |
(18,097,441) |
(16,424,385) |
|||||||
Pre-Tax Net Income (Loss) |
(24,883,659) |
(23,700,438) |
(14,808,749) |
(3,569,551) |
|||||||
Provision for Income Taxes |
4,494,049 |
3,638,695 |
19,740,595 |
14,898,064 |
|||||||
Net Income (Loss) |
$ |
(29,377,708) |
$ |
(27,339,133) |
$ |
(34,549,344) |
$ |
(18,467,615) |
|||
Less: Accumulated Preferred Stock Dividends for the Period |
(1,541,341) |
(2,508,677) |
(8,154,993) |
(7,802,809) |
|||||||
Net Income (Loss) Attributable to Common Stockholders |
$ |
(30,919,049) |
$ |
(29,847,810) |
$ |
(42,704,337) |
$ |
(26,270,424) |
|||
Earnings (Loss) per Share Attributable to Common Stockholders |
|||||||||||
Basic Earnings (Loss) per Share |
$ |
(0.43) |
$ |
(0.57) |
$ |
(0.66) |
$ |
(0.49) |
|||
Diluted Earnings (Loss) per Share |
$ |
(0.43) |
$ |
(0.57) |
$ |
(0.66) |
$ |
(0.49) |
|||
Weighted Average Number of Shares Outstanding – Basic |
71,680,200 |
53,637,003 |
64,535,245 |
53,637,003 |
|||||||
Weighted Average Number of Shares Outstanding – Diluted |
71,680,200 |
53,637,003 |
64,535,245 |
53,637,003 |
|||||||
Comprehensive Income (Loss) |
$ |
(29,377,708) |
$ |
(27,339,133) |
$ |
(34,549,344) |
$ |
(18,467,615) |
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars
For the Twelve Months Ended |
||||||
December 31, |
||||||
2023 |
2022 |
|||||
(Audited) |
(Audited) |
|||||
Cash Flows from Operating Activities: |
||||||
Net Income (Loss) for the Period |
$ |
(34,549,344) |
$ |
(18,467,615) |
||
Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities |
||||||
Depreciation & Amortization |
20,933,541 |
10,660,172 |
||||
Non-Cash Interest Expense |
4,024,604 |
4,118,391 |
||||
Impairment of Goodwill |
1,801,740 |
8,011,405 |
||||
Non-Cash Lease Expense |
7,648,531 |
3,910,679 |
||||
Deferred Taxes |
(2,090,967) |
502,070 |
||||
Loss on Disposition of Business Units |
1,968,807 |
4,684,369 |
||||
Change in Derivative Liabilities |
(15,870,233) |
(18,414,760) |
||||
Amortization of Debt Issuance Costs |
1,686,049 |
1,686,048 |
||||
Amortization of Debt Discount |
8,523,493 |
7,484,613 |
||||
(Gain) Loss on Investments, net |
(1,816) |
39,270 |
||||
Stock Based Compensation |
3,590,473 |
812,073 |
||||
Changes in Operating Assets & Liabilities (net of Acquired Amounts): |
||||||
Accounts Receivable |
927,259 |
(105,185) |
||||
Inventory |
4,571,069 |
789,399 |
||||
Prepaid Expenses & Other Current Assets |
1,579,349 |
(2,770,179) |
||||
Other Assets |
263,419 |
(248,682) |
||||
Change in Operating Lease Liabilities |
(7,498,128) |
(13,113,041) |
||||
Accounts Payable & Other Liabilities |
(3,241,850) |
11,845,245 |
||||
Income Taxes Payable |
17,934,967 |
5,270,074 |
||||
Net Cash Provided by (Used in) Operating Activities |
12,200,963 |
6,694,346 |
||||
Cash Flows from Investing Activities: |
||||||
Collection of Notes Receivable |
11,944 |
– |
||||
Cash Consideration for Acquisition of Business, net of Cash Acquired |
(15,834,378) |
(58,981,226) |
||||
Purchase of Fixed Assets |
(7,865,654) |
(14,007,892) |
||||
Purchase of Intangible Assets |
(2,750,000) |
– |
||||
Investment in Private Entity |
– |
(2,000,000) |
||||
Net Cash Provided by (Used in) Investing Activities |
(26,438,088) |
(74,989,118) |
||||
Cash Flows from Financing Activities: |
||||||
Payment on Notes Payable |
(5,354,218) |
(134,498) |
||||
Proceeds from Issuance of Common Stock |
– |
978,308 |
||||
Payment for Statutory Withholdings on RSU |
(108,978) |
– |
||||
Net Cash Provided by (Used in) Financing Activities |
(5,463,196) |
843,810 |
||||
Net (Decrease) in Cash & Cash Equivalents |
(19,700,321) |
(67,450,962) |
||||
Cash & Cash Equivalents at Beginning of Period |
38,949,253 |
106,400,216 |
||||
Cash & Cash Equivalents at End of Period |
$ |
19,248,932 |
$ |
38,949,253 |
||
Supplemental Disclosure of Cash Flow Information: |
||||||
Cash Paid for Interest |
$ |
17,896,954 |
$ |
15,243,990 |
||
Cash Paid for Income Taxes |
5,000,000 |
12,340,000 |
MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended December 31, 2023 and 2022
Expressed in U.S. Dollars
For the Three Months Ended |
For the Twelve Months Ended |
||||||||||
December 31, |
December 31, |
||||||||||
2023 |
2022 |
2023 |
2022 |
||||||||
Net Income (Loss) |
$ |
(29,364,680) |
$ |
(27,339,133) |
$ |
(34,549,344) |
$ |
(18,467,615) |
|||
Interest Expense, net |
8,112,391 |
6,827,557 |
32,069,082 |
30,139,645 |
|||||||
Provision for Income Taxes |
4,494,049 |
3,638,695 |
19,740,595 |
14,898,064 |
|||||||
Other (Income) Expense, net of Interest Expense |
516,180 |
14,367,747 |
(13,971,641) |
(13,715,260) |
|||||||
Depreciation & Amortization |
3,162,425 |
3,701,128 |
18,970,960 |
12,524,677 |
|||||||
Earnings Before Interest, Taxes, Depreciation and |
|||||||||||
Amortization (EBITDA) (non-GAAP) |
$ |
(13,079,635) |
$ |
1,195,994 |
$ |
22,259,652 |
$ |
25,379,511 |
|||
Non-Cash Stock Compensation |
1,597,157 |
883,890 |
2,219,319 |
2,672,713 |
|||||||
Deal Related Expenses |
2,196,733 |
1,914,820 |
5,528,048 |
6,822,111 |
|||||||
Capital Raise Related Expenses |
1,779 |
(257,271) |
38,559 |
533,958 |
|||||||
Inventory Adjustment to Fair Market Value for |
|||||||||||
Purchase Accounting |
5,792,488 |
– |
5,792,488 |
6,541,651 |
|||||||
One-Time Inventory Impairment |
7,353,972 |
– |
7,353,972 |
– |
|||||||
One-Time Goodwill Impairment |
1,801,740 |
8,011,405 |
1,801,740 |
8,011,405 |
|||||||
Severance |
111,752 |
263,374 |
537,584 |
334,910 |
|||||||
Retention Program Expenses |
– |
– |
505,655 |
– |
|||||||
Employee Relocation Expenses |
5,065 |
(3,750) |
70,107 |
15,360 |
|||||||
Pre-Operating & Dark Carry Expenses |
2,663,824 |
1,027,738 |
2,663,824 |
1,027,738 |
|||||||
One-Time Legal Settlements |
1,204,058 |
440,000 |
1,204,058 |
440,000 |
|||||||
Other Non-Recurring Items |
1,304,501 |
(191,674) |
3,436,773 |
230,858 |
|||||||
Adjusted EBITDA (non-GAAP) |
$ |
10,953,434 |
$ |
13,284,526 |
$ |
53,411,779 |
$ |
52,010,215 |
|||
Revenue |
43,324,815 |
40,147,287 |
172,447,786 |
159,379,219 |
|||||||
Adjusted EBITDA Percent |
25.3 % |
33.1 % |
31.0 % |
32.6 % |
View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-fourth-quarter-and-full-year-2023-financial-results-302101678.html
Cannabis
Hemp, Inc. Announces Significant Progress in Hemp Seed Meal Approval for Laying Hen Diets
Cannabis
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors
-
Cannabis2 weeks ago
TILT Holdings Reports Fourth Quarter and Full Year 2023 Results
-
Market2 weeks ago
Cannabis Packaging Market surpass $13.17 billion by 2030 – Exclusive Report by Coherent Market Insights
-
Cannabis2 weeks ago
Village Farms International Reports Q4 and 2023 Financials: Record Consolidated Sales for Q4
-
Cannabis2 weeks ago
Rick Simpson Oil California Introduces RSO Suppositories A New Path to Wellness Through Direct Absorption
-
Innocan2 weeks ago
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million
-
Cannabis2 weeks ago
Tilray Wellness Introduces New Superfood Products Powered by Hemp at Expo West
-
Cannabis2 weeks ago
Right On Brands, Inc. Continues Impressive Rollout, Announces 12th Store Opening
-
Cannabis2 weeks ago
BRIGHT GREEN ANNOUNCES ITS EXPANSION CONTINUATION WITH A $100 MILLION SOLAR POWERED GENERATION FIELD TO SUPPLY HEAT AND ELECTRICITY TO ITS DRUG PRODUCTION AND MANUFACTURING FACILITY.